Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2018-05-02 Earnings Release
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 2, 2018, reporting the issuance of a press release regarding financial results for the quarter ended March 31, 2018. The text explicitly states that the press release is furnished as an exhibit and is not deemed filed for certain regulatory purposes. The document is short (3541 characters) and primarily serves as an announcement of the earnings release rather than containing the financial results itself. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly financial results highlights via a press release attached as an exhibit.
2018-05-02 English
DEFA14A
Remuneration Information Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to a shareholder meeting. It includes information about voting instructions, meeting details, and proposals such as election of directors, advisory vote on executive compensation, ratification of auditors, and approval of an employee stock purchase plan. It does not contain the actual annual report or financial statements but rather materials to solicit shareholder votes. The presence of the term 'DEFA14A' and the description of proxy materials confirm this is a Remuneration Information filing, which typically includes executive compensation details and related proxy materials.
2018-04-05 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about the submission of a New Drug Application to the FDA, attached as an exhibit. There are no financial statements or detailed financial data included, and the document is relatively short (3379 characters). It is an announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-03-29 English
Regulatory Filings 2018
Regulatory Filings
2018-03-27 English
10-K
Annual Report FY 2017
2018-02-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.